BioPharmSignal logoBioPharmSignal

Biotech News

Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference

Xilio Therapeutics (XLO)Xilio TherapeuticsConference / presentation

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will present at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026 at 2:40 p.m. ET.

Related news

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

URGNUroGen Pharma2026-11-03 13:00 EST

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

XLOXilio Therapeutics2026-10-02 20:30 EST

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XLOXilio Therapeutics2026-09-28 11:30 EST

Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

MMSIMerit Medical2026-11-05 14:25 EST

Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry

STROSutro Biopharma2026-10-12 12:00 EST

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

View all latest news

Xilio Therapeutics

Tumor-Activated Immunotherapy Xilio Therapeutics engineers cytokines, antibodies, and T-cell engagers that remain masked until activated within the tumor microenvironment. XTX501 XTX501 combines PD-1 blockade with a masked IL-2 mechanism and is intended as a potential combination backbone across solid tumors. Masked T-Cell...

Recent company news

XLOXilio Therapeutics2026-11-03 21:30 EST

Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference

XLOXilio Therapeutics2026-10-02 20:30 EST

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XLOXilio Therapeutics2026-09-28 11:30 EST

Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

XLOXilio Therapeutics2026-09-02 20:30 EST

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XLOXilio Therapeutics2026-08-12 11:30 EST

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Stock data

Close
8.50 USD
Market cap
53.92M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States